Ginsenosides 20(S)-Rg3 exerts therapeutic effects in both cisplatin (GSRd 250 μg/mL for 24 h) and LPS (GSRd 10 mg/kg i.p. for 15 days)-induced AKI by targeting JNK-p53-caspase-3 axis and NF-κB signaling pathway (Kang et al., 2007; Wang et al., 2015; Han et al., 2016). This evidence concerns the gene TP53 and acute kidney injury.